Xbrane Biopharma Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 45
Employees
  • Stock Symbol
  • XBRANE
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $20.31
  • (As of Friday Closing)

Xbrane Biopharma General Information

Description

Xbrane Biopharma AB is a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion. The company has two segments that are Biosimilars and Long-acting Injectables and Administration and unallocated.

Contact Information

Website
www.xbrane.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Banvaktsvägen 22
  • 171 48 Solna
  • Sweden
+46 076-034 00 00

Xbrane Biopharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xbrane Biopharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$20.31 $20.30 $5.89 - $20.89 $451M 22.2M 42.9K -$1.28

Xbrane Biopharma Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 202,041 189,429 41,547 31,259
Revenue 766 740 63 12,982
EBITDA (24,831) (23,719) (18,952) (736)
Net Income (25,332) (24,514) (19,875) (1,521)
Total Assets 54,151 56,535 36,252 28,133
Total Debt 5,462 763 1,009 5,073
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xbrane Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xbrane Biopharma‘s full profile, request access.

Request a free trial

Xbrane Biopharma Executive Team (9)

Name Title Board Seat Contact Info
Martin Åmark Chief Executive Officer & Head of Investor Relations
Anette Lindqvist Chief Financial Officer & Head, Investor Relations
Siavash Bashiri Chief Operating Officer
David Vikström Ph.D Chief Technology Officer
Jan-Willem de Gier Chief Scientific Officer, Board Member & Founder
You’re viewing 5 of 9 executive team members. Get the full list »

Xbrane Biopharma Board Members (3)

Name Representing Role Since
000 00000000 00.0 Self Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Xbrane Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xbrane Biopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xbrane Biopharma‘s full profile, request access.

Request a free trial

Xbrane Biopharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 01-Sep-2015 0000000000 00.000 Biotechnology 000000 Å0000
To view Xbrane Biopharma’s complete investments history, request access »

Xbrane Biopharma Subsidiaries (1)

Company Name Industry Location Founded
00000 Biotechnology Milan, Italy 0000
To view Xbrane Biopharma’s complete subsidiaries history, request access »